US Patent

US11458145 — Methods of administering intravenous meloxicam in a bolus dose

Method of Use · Assigned to Baudax Bio Inc · Expires 2039-03-08 · 13y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering intravenous meloxicam in a bolus dose for the treatment of acute moderate to severe pain.

USPTO Abstract

The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Drugs covered by this patent

Mobic (MELOXICAM) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3318`	—	Mobic

Patent Metadata

Patent number: US11458145
Jurisdiction: US
Classification: Method of Use
Expires: 2039-03-08
Drug substance claim: No
Drug product claim: No
Assignee: Baudax Bio Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.